Approval · Notice of Compliance 1160 · 2000
LASIX: Notice of Compliance 1160
Issued August 15, 2000
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 1160
- Date
- August 15, 2000
- Company
- Aventis Pharma Inc.Laval, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Therapeutic class
- Diuretic
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LASIX | 02224690 | Cancelled Post Market |
| LASIX | 02224704 | Cancelled Post Market |
| LASIX | 02224712 | Cancelled Post Market |
| LASIX ORAL SOLUTION | 02224720 | Marketed |
Medicinal ingredients
- FUROSEMIDE 20 MG per TAB
- FUROSEMIDE 40 MG per TAB
- FUROSEMIDE 80 MG per TAB
- FUROSEMIDE 10 MG per ML